| Outcome Measures: |
Primary: Change From Baseline in Daily Insulin Dose at Week 24, Change in daily insulin dose following 24 weeks of therapy (i.e., daily insulin dose at Week 24 minus daily insulin dose at baseline), Baseline and Week 24 | Secondary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24, A1C is measured as the percentage of glycosylated hemoglobin. Change in A1C following 24 weeks of therapy (i.e., A1C at Week 24 minus A1C at baseline), Baseline and Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Change in FPG (before breakfast) following 24 weeks of therapy (i.e., FPG at Week 24 minus FPG at baseline), Baseline and Week 24|Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study, The fasting glucose target was defined as 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L)., Up to 24 weeks|Time to Achieve the Fasting Glucose Target, Fasting glucose target 3 consecutive days with a fingerstick glucose of 72 to 100 mg/dL (4.0 - 5.6 mmol/L). This analysis was the Kaplan-Meier estimated 50th percentile of time (days) to first attainment of target., Up to 24 weeks
|
